

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. 10071-037-999			APPLICATION NO. Unassigned 10/669,258	
				APPLICANT R. WILLIAMS et al.			
			FILING DATE 25 Sept 03			GROUP 1614	
			Concurrently herewith			1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,461,600 B1	10/2002	Ford	424	78.02	
	AB	6,387,957 B1	5/2002	Frome	514	647	
	AC	6,255,302 B1	7/2001	Kelly et al.	514	217.05	
	AD	6,251,948 B1	6/2001	Weber et al.	514	634	
	AE	6,251,903 B1	6/2001	Cai et al.	514	249	
	AF	6,245,781 B1	6/2001	Upadhyay et al.	514	321	
	AG	6,242,448 B1	6/2001	Kelly et al.	514	254.02	
	AH	6,239,194 B1	5/2001	Standke et al.	523	200	
	AI	6,225,324 B1	5/2001	Poss et al.	514	316	
	AJ	6,218,391 B1	4/2001	Arvanitis et al.	514	242	
	AK	6,211,171 B1	4/2001	Sawynok et al.	514	211.13	
	AL	6,197,830 B1	3/2001	Frome	514	654	
	AM	6,191,165 B1	2/2001	Ognyanov et al.	514	523	
	AN	6,191,131 B1	2/2001	He et al.	514	246	
	AO	6,174,192 B1	1/2001	Watanabe et al.	439	377	
	AP	6,172,097 B1	1/2001	Cordi et al.	514	396	
	AQ	6,133,282	10/2000	Horvath et al.	514	292	
	AR	6,117,855	9/2000	Carlson et al.	514	90	
	AS	6,096,771	8/2000	Kojima et al.	514	379	
	AT	6,025,369	2/2000	Rosenquist et al.	514	311	
	AU	6,017,961	1/2000	Flores et al.	514	561	
	AV	6,004,964	12/1999	Farrar et al.	514	255	
	AW	5,985,586	11/1999	Daggett et al.	435	7.21	
	AX	5,981,513	11/1999	Kruse et al.	514	91	
	AY	5,962,477	10/1999	Mak	514	327	
	AZ	5,948,389	9/1999	Stein	424	45	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (03/18/2009)

/Leslie A. Royds/ (03/18/2009)

	BC	5,888,494	3/1999	Farrar et al.	424	78.05	
	BD	5,869,521	2/1999	Farrar et al.	514	422	
	BE	5,863,916	1/1999	Cai et al.	514	249	
	BF	5,849,762	12/1998	Farrar et al.	414	327	
	BG	5,834,465	11/1998	Olney	514	226.2	
	BH	5,817,699	10/1998	Flores et al.	514	647	
	BI	5,811,078	9/1998	Maycock et al.	424	45	
	BJ	5,798,093	8/1998	Farrar et al.	424	45	
	BK	5,783,700	7/1998	Nichols et al.	546	162	
	BL	5,763,445	6/1998	Kruse et al.	514	255	
	BM	5,760,023	6/1998	Farrar et al.	514	150	
	BN	5,744,458	4/1998	Kruse et al.	514	91	
	BO	5,708,168	1/1998	Keana et al.	540	520	
	BP	5,688,955	11/1997	Kruse et al.	546	276.4	
	BQ	5,667,773	9/1997	Farrar et al.	424	78.05	
	BR	5,648,396	7/1997	Young et al.	514	651	
	BS	5,646,151	7/1997	Kruse et al.	514	255	
	BT	4,989,607	2/1991	Keusch et al.	128	640	
	BU	4,920,101	4/1990	Minaskanian et al.	514	24	
	BV	4,808,414	2/1989	Peck et al.	424	449	
	BW	4,801,586	1/1989	Minaskanian et al.	514	212	
	BX	4,755,535	7/1988	Minaskanian et al.	514	947	
	BY	4,751,087	6/1988	Wick	424	449	
	BZ	4,615,699	10/1986	Gale et al.	604	897	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CA	WO 95/23798	9/1995	PCT				
	CB	WO 95/18124	6/1995	PCT				
	CC	WO 95/16679	6/1995	PCT				
	CD	WO 94/13677	6/1994	PCT				
	CE	WO 94/13676	6/1994	PCT				
	CF	WO 94/13661	6/1994	PCT				
	CG	WO 94/13644	6/1994	PCT				
	CH	WO 94/13643	6/1994	PCT				
	CI	0 577 394 A1	1/1994	Europe				
	CJ	WO 93/10163	5/1993	PCT				
	CK	0 107 376 A1	5/1984	Europe				

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (03/18/2009)

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CL	"Handbook of Pharmaceutical Excipients," Edited by Arthur H. Kibbe, Ph.D., <u>Am. Pharm. Assoc.</u> , 3:292-294 , 2000.
CM	J. Sawynok et al., "Peripheral Antinociceptive Action of Amitriptyline in the Rat Formalin Test: Involvement of Adenosine," <u>Pain</u> , 80:45-55 , 1999.
CN	J. Sawynok et al., "Peripheral Antinociceptive Actions of Desipramine and Fluoxetine in an Inflammatory and Neuropathic Pain Test in the Rat," <u>Pain</u> , 82:149-158 , 1999.
CO	"Cardinal Manifestations and Presentations of Diseases," <u>Harrison's Principles of Internal Medicine</u> , Edited by A. Fauci et al., 14:1:53-58 , 1998.
CP	C. Stein et al., "Peripheral Morphine Analgesia," <u>Pain</u> , 71:119-121 , 1997.
CQ	T. Ghosh et al., Transdermal and Topical Drug Delivery Systems, "Types of Dermal Drug Delivery," <u>Interpharm Press, Inc.</u> , p. 7, 1997.
CR	T. Ghosh et al., Transdermal and Topical Drug Delivery Systems, "Transdermal and Dermal Therapeutic Systems," <u>Interpharm Press, Inc.</u> , pp. 87-93, 1997.
CS	T. Ghosh et al., Transdermal and Topical Drug Delivery Systems, "Transdermal and Dermal Therapeutic Systems: Current Status," <u>Interpharm Press, Inc.</u> , p. 33-112, 1997.
CT	Goodman & Gilman's The Pharmacological Basis of Therapeutics, Edited by J. Hardman et al., "Chapter 23 Opioid Analgesics and Antagonists," 9:521-525 , 1996.
CU	Goodman & Gilman's The Pharmacological Basis of Therapeutics, Edited by J. Hardman et al., "Chapter 23 Opioid Analgesics and Antagonists," 9:529 , 1996.
CV	Gennaro, Remington: The Science and Practice of Pharmacy, "Coarse Dispersions," 19(1):289 , 1995.
CW	Wolfe et al., "Massive Dextromethorphan Ingestion and Abuse," <u>Am J. Emerg Med. P.</u> , 13:174-176 , 1995.
CX	Jia-He Li et al., "Potent, Orally Active, Competitive N-Methyl-D-aspartate (NMDA) Receptor Antagonists Are Substrates for a Neutral Amino Acid Uptake System in Chinese Hamster Ovary Cells," <u>J. Med. Chem.</u> , 38:1955-1965 , 1995.
CY	Olney et al., "NMDA Antagonists as Neurotherapeutic Drugs, Psychotogens, Neurotoxins, and Research Tools for Studying Schizophrenia," <u>Neuropsychopharmacology</u> , 13(4):335-345 , 1995.
CZ	Yoneda et al., "Differential Profiles of Binding of a Radiolabeled Agonist and Antagonist at a Glycine Recognition Domain on the N-Methyl-D-Aspartate Receptor Ionophore Complex in Rat Brain," <u>J. Neurochem</u> , 62(1):102-112 , 1994.
DA	N. Michalun et al., "Milady's Skin Care and Cosmetic Ingredients Dictionary," Milady Publishing Company, p. 242, 1994.
DB	Bigge, "Structural Requirements for the Development of Potent N-Methyl-D-Aspartic Acid (NMDA) Receptor Antagonists," <u>Biochem. Pharmacol. P.</u> , 45(8):1547-1561 , 1993.
DC	T. Ghosh et al., "Methods of Enhancement of Transdermal Drug Delivery: Part IIA, Chemical Permeation Enhancers," <u>Pharm. Tech.</u> , 17:62-90 , 1993.
DD	T. Ghosh et al., "Methods of Enhancement of Transdermal Drug Delivery: Part IIB, Chemical Permeation Enhancers," <u>Pharm. Tech.</u> , 17:68-76 , 1993.
DE	P. Leeson, "Glycine-Site N-Methyl-D-Aspartate Receptor Antagonists," <u>Drug Design for Neuroscience</u> , pp. 338-381 , 1993.
DF	Wong et al., "Norfluoxetine Enantiomers as Inhibitors of Serotonin Uptake in Rat Brain," <u>Neuropsychopharmacology</u> , 8(4):337-344 , 1993.
DG	Albers et al., "Tolerability of Oral Dextromethorphan in Patients With a History of Brain Ischemia," <u>Clinical Neuropharmacology</u> , 15(6):509-514 , 1992.

DH	9/18/2009 "Pharmacological Strategies in CNS Trauma," <u>TiPS</u> , 13:29-35, 1992.
DI	Steinberg et al., "Dextromethorphan Alters Cerebral Blood Flow and Protects Against Cerebral Injury Following Focal Ischemia," <u>Neuroscience Letters</u> , 133:225-228, 1991.
DJ	Meldrum et al., "Excitatory Amino Acid Neurotoxicity and Neurodegenerative Disease," <u>TiPS</u> , 11:379-387, 1990.
DK	Willetts et al., "The Behavioral Pharmacology of NMDA Receptor Antagonists," <u>TiPS</u> , 11:423-428, 1990.
DL	"Percutaneous Absorption," edited by R. Bronaugh et al., 2 nd Ed., Contents, 1989.
DM	Mayer et al., "Sites of Antagonist Action on N-Methyl-D-Aspartic Acid Receptors Studied Using Fluctuation Analysis and a Rapid Perfusion Technique," <u>Journal of Neurophysiology</u> , 60(2):645-663, 1988.
DN	Thurkauf et al., "Synthesis, Absolute Configuration, and Molecular Modeling Study of Etoxadrol, a Potent Phencyclidine-Like Agonist," <u>J. Med. Chem.</u> , 31:2257-2263, 1988.
DO	G. Eccleston, "Emulsions," Encyclopedia of Pharmaceutical Technology, edited by J. Swarbrick et al. 5:137-189, 1988.
DP	J. Dohner, "Development of Processes and Equipment for Rate-Controlled Transdermal Therapeutic Systems," Transdermal Controlled Systemic Medications, edited by Y. Chien, pp 349-364, 1987.
DQ	H. Wolff et al., "Development of Processes and Technology for Adhesive-Type Transdermal Therapeutic Systems," Transdermal Controlled Systemic Medications, edited by Y. Chien, pp 365-378, 1987.
DR	D. Bova et al., "Product Development and Technology Transfer for Transdermal Therapeutic Systems," Transdermal Controlled Systemic Medications, edited by Y. Chien, pp 379-396, 1987.
DS	A. Jacobson et al., "Enantiomeric and Diastereomeric Dioxadrols: Behavioral, Biochemical and Chemical Determination of the Configuration Necessary for Phencyclidine-Like Properties," <u>J. Pharmacol. Exp. Ther. P.</u> , 243(1):110-117, 1987.
DT	M. Rogawski, "Therapeutic Potential of Excitatory Amino Acid Antagonists: Channel Blockers and 2,3-benzodiazepines," <u>TiPS</u> , 14:325-331, 1993.
DU	Grimwood et al., "Characterization of the Binding of [³ H]N-689,560, An Antagonist for the Glycine Site on the N-Methyl-D-Aspartate Receptor, to Rat Brain Membranes," <u>Molecular Pharmacology</u> , 41:923-930, 1992.
DV	Skolnick et al., "Monoaminergic Involvement in the Pharmacological Actions of Buspirone," <u>Br. J. Pharmac.</u> , 86:637-644, 1985.
DW	Wong et al., "A New Inhibitor of Norepinephrine Uptake Devoid of Affinity for Receptors in Rat Brain," <u>J. Pharm. Exp. Therap.</u> , 222(1):61-65, 1982.
DX	Kinemuchi et al., "Substrate Selectivity of Type A and Type B Monoamine Oxidase in Rat Brain," <u>J. Neurochem.</u> , 35(1):109-115, 1980.
DY	W. Griffin, "Classification of Surface-Active Agents by "HLB," <u>J. Soc. Cosmet. Chem.</u> , 311-326, 1949.

EXAMINER

/Leslie A. Royds/ (03/18/2009)

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.